Daver, N., Zeidner, J., Watts, J., Yuda, J., Levis, M., Montesinos, P., Papayannidis, C., Fukushima, K., Shima, T., Raffoux, E., Borate, U., Palmisiano, N., Brandwein, J., Heiblig, M., Miyazaki, Y., Ikezoe, T., Ooi, M., Wu, S., Wang, E., Vives, S., Strickland, S., Breems, D., Hosono, N., Ogawa, Y., Onodera, K., Brunner, A., Keiffer, G., Pardee, T., Shami, P., Eghtedar, A., Cai, H., Xu, B., Robson, P., Watanabe, A., Hitron, M., Shah, J., Kantarjian, H., Erba, H. (2025). Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. https://doi.org/10.1182/blood-2025-763